These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35984843)
1. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. Guin S; Liaw BK; Jun T; Ayers K; Patel B; O'Connell T; Deitz M; Klein M; Mullaney T; Prentice T; Newman S; Fink M; Zhou X; Schadt EE; Chen R; Oh WK PLoS One; 2022; 17(8):e0264800. PubMed ID: 35984843 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102 [TBL] [Abstract][Full Text] [Related]
3. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer. Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527 [TBL] [Abstract][Full Text] [Related]
5. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579 [TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis. Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066 [TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919 [TBL] [Abstract][Full Text] [Related]
9. Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Mokoala K; Reed J; Maseremule L; Ndlovu H; Hlongwa K; Maes A; Morgenstern A; Van de Wiele C Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2210-2218. PubMed ID: 36864360 [TBL] [Abstract][Full Text] [Related]
10. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775 [TBL] [Abstract][Full Text] [Related]
11. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223 [TBL] [Abstract][Full Text] [Related]
12. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. Caffo O; Wissing M; Bianchini D; Bergman A; Thomsen FB; Schmid S; Yu EY; Bournakis E; Sella A; Zagonel V; De Giorgi U; Tucci M; Gelderblom H; Galli L; Pappagallo G; Bria E; Sperduti I; Oudard S; Clin Genitourin Cancer; 2020 Feb; 18(1):69-76.e4. PubMed ID: 31767448 [TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response. Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244 [TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710 [TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O; Carthon B; Nazha B; Bilen MA Oncologist; 2021 Nov; 26(11):956-964. PubMed ID: 34096667 [TBL] [Abstract][Full Text] [Related]
18. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307 [TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. Ozaki K; Hatakeyama S; Narita S; Hata K; Yanagisawa T; Tanaka T; Togashi K; Hamaya T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Kimura T; Habuchi T; Ohyama C World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204 [TBL] [Abstract][Full Text] [Related]
20. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R; Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]